Built for market access, HEOR, launch, medical, and brand teams with one current decision, one named owner, and visible timing pressure.
Managed decision review
For pharma access or launch decisions that need a real review now.
NextConsensus helps pharma teams turn one timing-sensitive decision into a brief they can circulate. The brief puts the evidence, business stake, sign-off path, uncertainty, and what would trigger another review in one place before the decision drifts for another quarter.
The brief keeps the evidence, business stake, review path, uncertainty, and what would trigger another review on one page for internal review.
Why teams buy
Use it when waiting is already expensive and no one wants to circulate a weak brief.
The first brief should make the timing risk legible and keep the opening scope tight enough that a buyer can actually say yes to it.
These illustrative figures show the kind of operating stake the brief needs to make legible instead of leaving buried in side calculations.
Modeled stake $5.4M-$6.2M
Illustrative annual range at 100,000 covered lives in the current reference case.
Base case $4.50 PMPM
Illustrative baseline used to show that delay can carry a measurable operating cost.
Upper case $5.17 PMPM
Illustrative upper case when avoidable delay and leakage are more pronounced.
Illustrative values from the current cardiorenal reference case.
The opening work should prove usefulness quickly instead of asking for a broad strategy program or standing monitoring retainer.
Start with one access, launch, or evidence question that already has visible downside if it stays unresolved.
Keep the opening work tight around a single therapy area, a focused account set or patient segment, and a brief built for real internal circulation.
Use the first brief to prove usefulness quickly, then expand only if the work earns a longer relationship.
If the first brief does not hold up, the right next step is to narrow or stop, not to widen the scope.
What the brief has to make clear
The product is the brief, not the explanation around it.
The first brief should lock down the decision, the stake, the reviewers, and the point at which the team pauses or looks again.
Decision-brief anatomy What a pharma team needs on one page
Current evidence
What the team could reasonably rely on now, with the source trail intact.
Commercial stake
Why waiting is expensive enough to justify a real internal review now.
Sign-off path
Which reviewers, functions, or committees need to weigh in before the move can go anywhere.
Pause conditions
What would force the team to narrow, stop, or revisit the call if the case changes.
Earlier review only counts if the team can still challenge the brief, narrow it, or step back when the facts change.
The issue does not need to be solved yet. It does need to be specific enough that the first brief can be defined fast.
If the issue still needs a generic scan, it is not narrow enough yet for a managed decision review.
Boundary before work starts
The opening conversation should feel safe, narrow, and operationally serious.
Trust should come from a visible data boundary, a scoped intro call, and a role boundary the reader can understand before any material is shared.
Start with the decision, the cost of delay, the review owner, and the blocker. Move to secure handoff only if later scope truly needs sensitive material.
The outcome should be a narrow brief definition, a visible review path, and a clear next step instead of a long discovery loop.
If those roles would collide on the same call, one side is declined, paused, or separated before work proceeds.
See the intake boundary, secure-handoff rule, intro-call output, and role-separation policy in one place.
Next step
Start with the sample brief. If it looks usable, send a short note.
Read the sample first so you can judge the brief before sharing context. Most first conversations do not require PHI, patient records, or a long intake memo.